Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

计划入组 241 人 · 首次发布于 2019 年 1 月 16 日

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability

计划入组 256 人 · 首次发布于 2014 年 10 月 21 日

A Study of NT 201 Doses in the Treatment of Platysma Prominence

计划入组 73 人 · 首次发布于 2023 年 3 月 17 日

SKP-0150

SOC-0150

BEVCO NT PTY LTD

Australia

NT PHARMA INTERNATIONAL COMPANY LIMITED

Hong Kong, China

Microbot Medical, Inc.

Israel

NodThera's NLRP3 Inhibitor Ruvonoflast Shows Promising Anti-Inflammatory Effects in Cardiovascular Risk Patients

Rezera's Oral NLRP3 Inhibitor Ruvonoflast Hits Primary Inflammation Endpoint in Phase 2 RESOLVE-1, Phase 3 PAD Trial Planned for 2027

Revolution Medicines' RMC-6236: A Novel Pan-RAS(ON) Inhibitor Shows Promise in 'Undruggable' Tumors